A new class of cholesterol-lowering medicines from Pfizer Inc. and Amgen Inc. may struggle to meet sales projections, as latest treatment guidelines suggest doctors should prescribe only drugs proven to help the heart.
Medtronic Inc. said it will make the data on its embattled bone-growth product Infuse available to the public and pay for two independent analyses of the information in a move the company says may set a new industry standard.
GlaxoSmithKline Plc ’s study of its once best-selling diabetes pill Avandia doesn’t prove the drug is safe, according to U.S. regulators considering whether to recall it amid doctors’ concerns it causes heart complications.
General Mills Inc. ’s Cheerios are among the foods that should be held to the same scientific standards as pharmaceuticals when promoted as having health benefits, a report ordered by U.S. regulators said today.
Medtronic Inc. ghost-wrote sections of medical papers and paid physician authors hundreds of millions of dollars in “consulting fees” to promote its bone- growth product Infuse, a U.S. Senate investigation found.
An experimental drug from Merck & Co. raised levels of good cholesterol, slashed bad cholesterol and may have helped patients avert heart complications, without the safety risks that prompted Pfizer Inc. to abandon a similar product four years ago.
U.S. patients of doctors who went to medical school outside the country and weren’t American citizens had a 9 percent lower death rate on average than those whose doctors trained at home, a study showed.